Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04489368
Registration number
NCT04489368
Ethics application status
Date submitted
23/07/2020
Date registered
28/07/2020
Date last updated
28/12/2022
Titles & IDs
Public title
Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning
Query!
Scientific title
Pathological Response Prediction to Neo-adjuvant Chemoradiotherapy in Esophageal Carcinoma and Comparison of Engineered Features Versus Deep Learning Models
Query!
Secondary ID [1]
0
0
RGCIRC/IRB/80/2020
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
QARC
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Esophageal Neoplasm
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Oesophageal (gullet)
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Other - Neo-Adjuvant Radiotherapy
Treatment: Drugs - Neo-Adjuvant Chemotherapy
Treatment: Surgery - Esophagectomy
Study Group - Patients undergoing NA-CCRT followed by Surgery
Treatment: Other: Neo-Adjuvant Radiotherapy
Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
Treatment: Drugs: Neo-Adjuvant Chemotherapy
Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
Treatment: Surgery: Esophagectomy
Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Intervention code [3]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Develop models to predict pCR based on pre-neoadjuvant imaging modalities
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
August 2021
Query!
Primary outcome [2]
0
0
Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
January 2020
Query!
Eligibility
Key inclusion criteria
- ECOG Performance Status: 0-2
- Patients with histopathological or cytopathological confirmed malignancy of the
esophagus
- Histology: Squamous Cell Carcinoma and Adenocarcinoma
- Patients should have received NeoAdjuvant Concurrent Chemoradiation (NACCRT) followed
by Surgery
- All therapeutic interventions (Radiotherapy, Chemotherapy & Surgery) delivered within
participating institutions
- At least one pre-NACCRT DICOM imaging dataset (HRCT/ 18-FDG PET-CT/ Radiotherapy
planning CT) for each patient
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients with any metallic implants in the region of interest
- Patient with locally advanced disease or metastatic disease (T4 disease, Fistula,
metastases)
- Patients with prior history of radiotherapy in the same region
- Patients developing a second malignancy in the esophagus
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/01/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2023
Query!
Actual
Query!
Sample size
Target
150
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Illawarra Cancer Care Centre - Wollongong
Query!
Recruitment postcode(s) [1]
0
0
2500 - Wollongong
Query!
Recruitment outside Australia
Country [1]
0
0
India
Query!
State/province [1]
0
0
Delhi
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Dr Kundan Singh Chufal
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
In esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy (NA-CCRT) followed by
surgery is the current standard of care and ample evidence has accumulated supporting the
view that complete pathological response (pCR) is a positive prognostic marker for improved
outcomes. Predicting the probability of achieving pCR prior to neoadjuvant treatment could
permit modification of treatment protocols for those patients unlikely to achieve pCR.
Radiomics is a new entrant in the field of imaging where specific features are derived from
the intensity and distribution pattern of pixels based on a region-of-interest (ROI). The
features thus extracted can then be used for prediction modelling similar to other -omics
datasets. Preliminary investigations examining its utility have been performed and its
applications have thus far focused on screening and survival prediction after treatment. Due
to the multi-dimensional nature of data extracted using radiomics, Artificial Intelligence
(AI) methods are ideally suited for analysing and modelling radiomic features.
Machine Learning (ML) and Deep Learning (DL)[utilising Convolutional Neural Networks (CNN)]
are both part of the AI framework. In contrast to ML, DL is a new entrant and has been
utilised by some medical researchers for modelling using prediction-type algorithms. Besides
significantly reducing the workflow associated with Radiomics-based research, feature
engineering and modelling using DL are immune to the effects of incorrect ROI delineation.
However, the main limitation of DL is the 'blackbox' effect, in which the underlying basis of
a CNN is not known. This has been mitigated in part by the visualisation of activation maps
directly on the image dataset to prove biological plausibility of predictions. The
comparative performance of both types of modelling is also not known.
Our objective is to investigate pCR probability in our study population using radiomics-based
ML and AI-based modelling. We will also investigate the comparative performance of both
modelling techniques. For DL based prediction modelling, we will attempt to provide
biological plausibility on the basis of activation maps.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04489368
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Kundan S Chufal, MD
Query!
Address
0
0
Rajiv Gandhi Cancer Institute & Research Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04489368
Download to PDF